Bio­phar­ma man­u­fac­tur­ers call for clar­i­ty on FDA's ad­vanced des­ig­na­tion guid­ance 

Phar­ma com­pa­nies are ex­press­ing fears that the FDA’s new ad­vanced man­u­fac­tur­ing tech des­ig­na­tion guid­ance could “bur­den” the agency, ac­cord­ing to com­ments re­cent­ly made pub­lic.

The 13-page guid­ance pub­lished in De­cem­ber out­lined ways to in­cor­po­rate ad­vanced man­u­fac­tur­ing tech­nol­o­gy (AMT) dur­ing the man­u­fac­tur­ing and de­vel­op­ment of drugs. Ac­cord­ing to the guid­ance, com­pa­nies will be giv­en pri­or­i­ty des­ig­na­tion by the FDA if they use AMT to im­prove drug qual­i­ty or to com­mer­cial­ly man­u­fac­ture drugs in short­age.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER